Table 3 compiles the complete information on molecules targeting TGF-β signaling components, including those mentioned above and others. Despite having a favorable tolerability profile in metastatic patients, translating these pharmacological interventions from bench to bedside has proven challenging, given the apparent heterogeneity of HCC tumors [321,322,323]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.